Literature DB >> 11880455

Staphylococcus heterogeneously resistant to vancomycin in China and antimicrobial activities of imipenem and vancomycin in combination against it.

Wu Benquan1, Tang Yingchun, Zhang Kouxing, Zhang Tiantuo, Zhu Jiaxing, Tan Shuqing.   

Abstract

Of 115 methicillin-resistant Staphylococcus strains collected from sputum specimens, 34 strains reduced susceptibility to vancomycin, 9 of which emerged as heterogeneous vancomycin-resistant strains (hetero-VRS), with various degrees of vancomycin resistance at a frequency of 10(-6) or higher. Seventy-six percent (19 of 25) of non-hetero-VRS and 100% (9 of 9) of hetero-VRS were susceptible to synergistic treatment with vancomycin and imipenem. Clinical clearance between 9 hetero-VRS and 25 non-hetero-VRS had an obvious statistical significance (P = 0.001). The hetero-VRS may play an important role in vancomycin therapy failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880455      PMCID: PMC120272          DOI: 10.1128/JCM.40.3.1109-1112.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  The effects of vancomycin and beta-lactam antibiotics on vancomycin-resistant Staphylococcus aureus.

Authors:  I Haraga; S Nomura; A Nagayama
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

2.  Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals.

Authors:  O Chesneau; A Morvan; N E Solh
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

3.  Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method.

Authors:  M Kuroda; K Kuwahara-Arai; K Hiramatsu
Journal:  Biochem Biophys Res Commun       Date:  2000-03-16       Impact factor: 3.575

4.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

5.  Combinations of vancomycin and beta-lactams are synergistic against staphylococci with reduced susceptibilities to vancomycin.

Authors:  M W Climo; R L Patron; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 6.  Molecular evolution of MRSA.

Authors:  K Hiramatsu
Journal:  Microbiol Immunol       Date:  1995       Impact factor: 1.955

7.  [High risk factors lead to noscomial pulmonary infections caused by MRSA].

Authors:  B Wu; Y Tang; J Zhu
Journal:  Zhonghua Jie He He Hu Xi Za Zhi       Date:  2000-07

8.  [Relation between candidiasis and nutrition of patients and MRSA infection].

Authors:  S Takeda; K Kono; K Arakawa
Journal:  Kansenshogaku Zasshi       Date:  1997-09

9.  Glycopeptide susceptibility profiles of Staphylococcus haemolyticus bloodstream isolates.

Authors:  F Biavasco; C Vignaroli; R Lazzarini; P E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

10.  Predicting methicillin resistance and the effect of inadequate empiric therapy on survival in patients with Staphylococcus aureus bacteremia.

Authors:  M C Roghmann
Journal:  Arch Intern Med       Date:  2000-04-10
View more
  5 in total

1.  In vitro and in vivo synergistic activities of linezolid combined with subinhibitory concentrations of imipenem against methicillin-resistant Staphylococcus aureus.

Authors:  Cédric Jacqueline; Dominique Navas; Eric Batard; Anne-Françoise Miegeville; Virginie Le Mabecque; Marie-France Kergueris; Denis Bugnon; Gilles Potel; Jocelyne Caillon
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin-resistant S. aureus isolates.

Authors:  Adam M Pitz; Fang Yu; Elizabeth D Hermsen; Mark E Rupp; Paul D Fey; Keith M Olsen
Journal:  J Clin Microbiol       Date:  2010-10-20       Impact factor: 5.948

3.  Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years.

Authors:  Adina C Musta; Kathleen Riederer; Stephen Shemes; Patrick Chase; Jinson Jose; Leonard B Johnson; Riad Khatib
Journal:  J Clin Microbiol       Date:  2009-04-15       Impact factor: 5.948

4.  Isolation and partial characterization of cyclic lipopeptide antibiotics produced by Paenibacillus ehimensis B7.

Authors:  Zhaohui Huang; Yu Hu; Linfei Shou; Mingxu Song
Journal:  BMC Microbiol       Date:  2013-04-17       Impact factor: 3.605

5.  Synergistic effect of vancomycin combined with cefotaxime, imipenem, or meropenem against Staphylococcus aureus with reduced susceptibility to vancomycin

Authors:  Arpasiri Srisrattakarn; Chonthicha Chaiyapoke; Sirikarn Booncharoen; Sujintana Wongthong; Aroonwadee Chanawong; Patcharaporn Tippayawat; Ratree Tavichakorntrakool; Aroonlug Lulitanond
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.